^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    idarubicin hydrochloride

    i
    Other names: IDA, DMDR, FCE 22723, IMI 30, NSC 256439
    Company:
    Generic mfg.
    Drug class:
    Topoisomerase II inhibitor, DNA cross linking agent
    Related drugs:
    9d
    Pevonedistat, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia (clinicaltrials.gov)
    P1/2, N=53, Active, not recruiting, University of Southern California | Trial completion date: Dec 2026 --> Dec 2027 | Trial primary completion date: Jun 2026 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    cytarabine • idarubicin hydrochloride • pevonedistat (MLN4924) • Starasid (cytarabine ocfosfate)
    12d
    Ivosidenib and Combination Chemotherapy for the Treatment of IDH1 Mutant Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov)
    P1, N=2, Terminated, Northwestern University | Active, not recruiting --> Terminated; Low accrual
    Trial termination
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • UGT1A1 (UDP glucuronosyltransferase family 1 member A1)
    |
    IDH1 R132
    |
    cytarabine • Tibsovo (ivosidenib) • idarubicin hydrochloride • fludarabine IV • Neupogen (filgrastim) • Starasid (cytarabine ocfosfate)
    19d
    Phase 1/2 FLAG-IDA, VEN and Asciminib in CML and Ph+ AML (clinicaltrials.gov)
    P1/2, N=30, Not yet recruiting, M.D. Anderson Cancer Center
    New P1/2 trial
    |
    ABL1 (ABL proto-oncogene 1)
    |
    Venclexta (venetoclax) • cytarabine • Blincyto (blinatumomab) • idarubicin hydrochloride • Scemblix (asciminib) • fludarabine IV • Neupogen (filgrastim)
    28d
    HAV Versus DAV/IAV Induction Regimen in Elderly Patients With AML (clinicaltrials.gov)
    P2, N=41, Active, not recruiting, Institute of Hematology & Blood Diseases Hospital, China | Recruiting --> Active, not recruiting | N=60 --> 41 | Trial completion date: Jun 2027 --> Jun 2028 | Trial primary completion date: Jun 2026 --> Dec 2027
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date
    |
    Venclexta (venetoclax) • cytarabine • azacitidine • daunorubicin • idarubicin hydrochloride • Synribo (omacetaxine mepesuccinate)
    29d
    PARADIGM: Venetoclax + Azacitidine vs. Induction Chemotherapy in AML (clinicaltrials.gov)
    P2, N=172, Active, not recruiting, Massachusetts General Hospital | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    Venclexta (venetoclax) • azacitidine • Vyxeos (cytarabine/daunorubicin liposomal formulation) • idarubicin hydrochloride
    1m
    Direct interaction between cancer cells and fibroblasts promotes early chemoresistance to standard-of-care drug therapy in small cell lung cancer (SCLC). (PubMed, bioRxiv)
    Here, we show that direct physical contact between small cell lung cancer (SCLC) cells and lung fibroblasts induces early resistance to standard-of-care chemotherapeutic agents, etoposide and cisplatin. A high-throughput drug screening identified idarubicin as a compound that retains efficacy despite fibroblast-mediated protection, suggesting it could bypass microenvironment-induced resistance early on. Together, our findings identify direct tumor-fibroblasts contact as an early driver of chemoresistance and highlight a potential therapeutic strategy targeting cell-cell interactions within the tumor microenvironment.
    Journal
    |
    YAP1 (Yes associated protein 1)
    |
    cisplatin • etoposide IV • idarubicin hydrochloride
    1m
    BGB-11417-2001-IIT: Phase II Study of Sonrotoclax Combined With Chemotherapy in the Treatment of Newly Diagnosed Acute Myeloid Leukemia (clinicaltrials.gov)
    P2, N=47, Active, not recruiting, Shanghai Jiao Tong University School of Medicine | Not yet recruiting --> Active, not recruiting
    Enrollment closed
    |
    cytarabine • azacitidine • daunorubicin • idarubicin hydrochloride • Beqalzi (sonrotoclax)
    1m
    Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML) (clinicaltrials.gov)
    P3, N=875, Recruiting, Stichting Hemato-Oncologie voor Volwassenen Nederland | N=423 --> 875
    Enrollment change • Trial initiation date
    |
    NPM1 (Nucleophosmin 1) • KMT2A (Lysine Methyltransferase 2A)
    |
    NPM1 mutation
    |
    cytarabine • daunorubicin • idarubicin hydrochloride • bleximenib (JNJ-6617)
    1m
    HEC73543 Versus Salvage Chemotherapy in R/R FLT3-ITD AML (clinicaltrials.gov)
    P3, N=324, Recruiting, Sunshine Lake Pharma Co., Ltd. | Trial completion date: Jun 2027 --> May 2028 | Trial primary completion date: Mar 2026 --> Nov 2027
    Trial completion date • Trial primary completion date
    |
    FLT3 (Fms-related tyrosine kinase 3)
    |
    FLT3 mutation
    |
    cytarabine • azacitidine • decitabine • idarubicin hydrochloride • fludarabine IV • clifutinib (HEC73543)
    2ms
    Role of FMS-Like Tyrosine Kinase 3 (FLT3) Inhibitors in a Patient With T/Myeloid Acute Leukemia With an FLT3 Mutation. (PubMed, Cureus)
    The patient was initially treated with a hybrid induction regimen of FLAG-IDA (fludarabine, arabinofuranosyl cytidine, granulocyte colony-stimulating factor (G-CSF)-idarubicin) plus vincristine and prednisone, followed by reinduction with decitabine and venetoclax due to persistent disease. In this case, the delayed introduction of midostaurin was favored to minimize toxicity during induction. Ongoing studies are needed to determine the best treatment strategies and timing for targeted therapies in this rare leukemia subtype.
    Journal
    |
    FLT3 (Fms-related tyrosine kinase 3)
    |
    FLT3-ITD mutation • FLT3 mutation
    |
    Venclexta (venetoclax) • midostaurin • decitabine • vincristine • prednisone • idarubicin hydrochloride • fludarabine IV
    2ms
    Pharmacological inhibition of the PERK pathway modulates hepatocellular carcinoma growth and immune signaling. (PubMed, FEBS Open Bio)
    Finally, AMG PERK 44 did not enhance idarubicin efficacy and caused no major off-target effects. These findings highlight the context-dependent role of PERK in the HCC microenvironment and its implications for targeting UPR pathways in liver cancer. Impact statement This study provides an evaluation of PERK as a therapeutic target in hepatocellular carcinoma by demonstrating that its inhibition does not produce the anticipated anti-tumor effects in advanced disease, but instead exerts nuanced, context-dependent influences on the tumor microenvironment.
    Journal
    |
    ER (Estrogen receptor) • TGFB1 (Transforming Growth Factor Beta 1) • MAPK4 (Mitogen-Activated Protein Kinase 4) • PERK (Pancreatic EIF2-Alpha Kinase) • CTGF (Connective tissue growth factor) • EIF2AK3 (Eukaryotic Translation Initiation Factor 2 Alpha Kinase 3)
    |
    idarubicin hydrochloride
    2ms
    NCI-2023-03572: Combination Chemotherapy (FLAG-Ida) With Pivekimab Sunirine (PVEK [IMGN632]) for the Treatment of Newly Diagnosed Adverse Risk Acute Myeloid Leukemia and Other High-Grade Myeloid Neoplasms (clinicaltrials.gov)
    P1, N=30, Active, not recruiting, Fred Hutchinson Cancer Center | Recruiting --> Active, not recruiting | Trial completion date: Dec 2029 --> May 2029 | Trial primary completion date: Dec 2026 --> May 2026
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    IL3RA (Interleukin 3 Receptor Subunit Alpha)
    |
    Chr t(15;17)
    |
    cytarabine • idarubicin hydrochloride • fludarabine IV • Decnupaz (pivekimab sunirine-pvzy) • Starasid (cytarabine ocfosfate)